Zolem

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolem

What is Zolem? Identity and General Purpose

Property Description
Active ingredient Omeprazole (INN)
Form Delayed-release capsule
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Powerful, prolonged acid suppression
Origin Synthetic (Substituted benzimidazole)

What Type of Medicine is Zolem (Omeprazole)?

Zolem is the proprietary name for a medicine containing the active ingredient Omeprazole, which is categorized as a Proton Pump Inhibitor (PPI). This compound is a synthetic substituted benzimidazole derivative, representing the first clinically recognized drug in its class. This classification aligns with the pharmacological characteristics of the drug compared to older acid-reducing medications. Omeprazole's foundational role in modern acid suppressive therapy is recognized globally, leading to its inclusion on the WHO Model List of Essential Medicines. It is typically supplied as a prescription-only medicine (Rx), reflecting its potency and systemic action.


Composition, Form, and General Purpose

Zolem is a single-ingredient product administered in an oral dosage form, specifically as a delayed-release capsule filled with enteric-coated pellets. This pharmaceutical structure is used because Omeprazole is an acid-sensitive prodrug that must pass through the stomach unharmed to be properly absorbed. The enteric-coated pellets protect the compound from degradation by gastric acid, providing the required pharmaceutical design for systemic action. The general purpose of Zolem's mechanism is to provide powerful, prolonged acid suppression, which is the clinical goal when managing symptoms like frequent heartburn or acid reflux.


How Does Zolem Differ From Other Acid-Reducing Agents?

Zolem's key distinction lies in its mechanism of irreversible inhibition of the H^+K^+-ATPase enzyme, or acid pump, within the stomach's parietal cell lining. This action, which shuts down the final step of acid secretion, is more potent and prolonged than the temporary effect offered by H2-receptor blockers or neutralizing antacids. While many generic forms of Omeprazole exist, Zolem is a defined brand formulation, ensuring consistent quality and drug delivery characteristics based on its specific manufacturing standards.

Regulatory References

  1. Omeprazole on WHO EML
  2. Omeprazole (StatPearls/NIH)
  3. Omeprazole (DrugBank)

What side effects are possible with Zolem?

Important Safety Information and Adverse Reactions

Zolem (zolpidem) is associated with several safety considerations, including a Boxed Warning regarding complex sleep behaviors. This is the most serious warning required by the FDA.

Serious and Clinically Significant Risks

  • Complex Sleep Behaviors: Activities performed while not fully awake (e.g., "sleep-driving," sleepwalking, preparing and eating food, making phone calls) have been reported, potentially resulting in serious injury or death. This risk exists even at recommended doses and is heightened by concomitant use of alcohol or other CNS depressants.
  • Anaphylactic/Anaphylactoid Reactions: Severe, potentially fatal allergic reactions, including angioedema (swelling of the tongue, glottis, or larynx) which can cause airway obstruction, have occurred. The drug is contraindicated in patients who have previously experienced this or complex sleep behavior with zolpidem.
  • Central Nervous System (CNS) Depression: The drug causes drowsiness and slowed mental and physical processes. This may lead to impaired alertness, motor coordination, and increased risk of falls, especially in the elderly. Next-day impairment (drowsiness and driving risk) is a recognized concern, and the risk increases with higher doses.
  • Psychiatric and Behavioral Changes: New or worsening depression and suicidal ideation, along with abnormal thoughts and behavioral changes such as agitation, hallucinations, and decreased inhibition, have been reported.

Common Adverse Reactions

The most commonly observed side effects include dizziness, headache, and drowsiness (or next-day residual somnolence). Gastrointestinal issues like diarrhea and nausea have also been reported.

Population-Specific Safety Notes

Lower initial doses are generally recommended for women and elderly or debilitated patients due to higher blood concentrations and increased sensitivity to adverse effects. The drug is not recommended for patients with severe hepatic impairment due to the risk of hepatic encephalopathy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Zolem

Overdose scope Details (as stated in regulatory labels)
Documented overdose presentations Symptoms involve the Central Nervous System (CNS) and range from somnolence (drowsiness) to coma and loss of consciousness.
Physiological systems affected CNS, Respiratory system, and Cardiovascular system; severe outcomes include respiratory and cardiovascular compromise.
Dose-related or exposure-related factors Overdose involving Zolem alone is typically non-fatal. Increased severity and higher risk to life are reported with co-ingestion of alcohol or other CNS depressants.
Emergency-response statements Immediate medical help is required to manage effects. General symptomatic and supportive measures must be employed, with special attention to maintaining respiratory and cardiovascular function.
Specific management notes The benzodiazepine antagonist flumazenil may be used to reverse the CNS depressant effects of Zolem, though the benefit may be limited. Zolem has been demonstrated to be non-dialyzable; hemodialysis is therefore ineffective as a primary elimination technique.

Connection to the overall overdose profile

Official regulatory documents define the overdose profile by stating the range of CNS depression, from simple drowsiness to life-threatening respiratory or cardiac compromise, particularly in mixed ingestions. The labels explicitly dictate that immediate medical attention is necessary and guide the emergency response by identifying flumazenil as a potential treatment agent, while noting that supportive care for vital functions is paramount.

Therapeutic Uses of Zolem

What Zolem Treats: Main Uses and Benefits

Zolem is used in situations involving certain distressing symptoms associated with various conditions, such as those characterized by episodic symptom patterns and acute episodes. It is recognized for use across domains where additional symptomatic support is needed.

It is relevant for easing symptoms during periods of heightened distress and providing temporary assistance for overwhelming symptom manifestations. The medicine is relevant in contexts involving heightened systemic burden where symptoms may create noticeable interference with routine activities or become temporarily overwhelming. The medication is applied in clinical settings that involve acute or unstable symptom patterns, particularly when conditions produce significant symptomatic burden.

This medicine may assist with managing groups of symptoms that escalate temporarily, contributing to improved comfort during periods of heightened symptoms. The medicine helps ease the overall symptom load and supports the patient during difficult episodes by easing distress.


Quick Fact: Relevant for Acute Discomfort

Zolem is relevant in contexts involving increased discomfort or tension where short-term symptom stabilization is required. The medicine is relevant for easing symptoms related to heightened physiological activity and managing those that create noticeable functional strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zolem (Zolpidem)

The population eligibility for Zolem is defined by official regulatory documents, distinguishing between absolute contraindications and conditions that require restricted use.

Contraindicated Populations

Use of Zolem is strictly prohibited in patients with known hypersensitivity to the drug or its components. It is also contraindicated in individuals with severe hepatic insufficiency (severe liver impairment), sleep apnoea syndrome, myasthenia gravis, or severe respiratory insufficiency. A history of experiencing complex sleep behaviors (such as sleep-driving) after taking the drug also serves as an absolute contraindication for future use.

Conditional and Restricted Use

Specific populations require caution and use only under close medical supervision or at a lower dose. These groups include elderly or debilitated patients and individuals with mild to moderate hepatic impairment. Patients with a history of alcohol or substance abuse must use the medicine with extreme caution due to the risk of dependence. Use is not recommended or contraindicated in children and adolescents under 18 years of age as safety and effectiveness have not been established. Use in women who are pregnant (especially in the third trimester) or breastfeeding is generally not recommended.

What should I know about interactions with other medicines?

Zolem (Zolpidem) is a central nervous system (CNS) depressant, and its use with other medicines or substances that also slow brain activity can lead to potentially serious additive effects. This interaction profile is defined by two key mechanistic areas: pharmacodynamic effects and metabolic pathways.

Clinically Significant Interactions

CNS Depressants and Alcohol: Concomitant use with alcohol or other CNS depressants (e.g., opioids, benzodiazepines, tricyclic antidepressants, certain antipsychotics) increases the risk of severe CNS depression, including profound sedation, respiratory depression, coma, and death. If combination use with opioids is necessary, regulatory guidance recommends restricting the dosage and duration to the minimum required and monitoring closely for signs of respiratory depression.

CYP450 Enzyme System: Zolem is metabolized by the Cytochrome P450 enzyme system, primarily CYP3A4. Interactions with medicines that modify this enzyme's activity can alter Zolem's concentration in the body.

  • CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, certain antibiotics): These can increase the exposure to and effects of Zolem, raising the risk of excessive sedation and impairment.
  • CYP3A4 Inducers (e.g., rifampin, St. John's Wort): These can decrease the exposure to and effectiveness of Zolem by speeding up its metabolism.

Food: Taking Zolem with or immediately after a meal may slow down its absorption and delay its effects. The risk of next-day psychomotor impairment, including impaired driving, is also increased if Zolem is taken with less than a full seven to eight hours of sleep remaining.

Mechanism of Action

Mechanism of Action

Zolem acts as a Positive Allosteric Modulator (PAM) on the Gamma-aminobutyric acid type A (GABAA) receptor complex within the central nervous system. This receptor is the primary mediator of inhibitory signaling in the brain. By binding to a specific site distinct from the GABA binding pocket, Zolem enhances the effect of the inhibitory neurotransmitter GABA, increasing the frequency of the receptor's chloride ion (Cl^-) channel opening.

This interaction is characterized by a high affinity for GABAA receptors containing the alpha1 subunit, concentrating its inhibitory action in brain regions regulating arousal. The resulting influx of negative chloride ions causes neuronal hyperpolarization, which fundamentally reduces overall neuronal excitability and the neuron's ability to fire. This molecular cascade contributes to the physiological change of decreased arousal, characterized by a reduction in the time required for the onset of central nervous system inhibition.

Dosage and Administration Information

Administration Guidelines for Zolem (Alprazolam)

The following describes the use and administration procedures for Zolem (alprazolam). The instructions cover dosing, frequency, and specific handling requirements, but do not address indications, safety, or effectiveness.

Field Administration Instructions
Route of Administration Oral (tablet, solution) or Sublingual (Orally Disintegrating Tablet, ODT).
Dosing Schedule Initial doses are low, typically 0.25 mg to 0.5 mg, and must be individually titrated to the lowest effective level by a healthcare professional.
Frequency Immediate-Release (IR) formulations are typically taken in divided doses up to three times daily. Extended-Release (XR) formulations are taken once daily.
Administration Conditions Can be taken without regard to meals. XR tablets must be swallowed whole and must not be crushed, chewed, or broken. ODTs must dissolve completely on the tongue.
Age-Group Rules Geriatric or Debilitated Patients require a lower starting dose, such as 0.25 mg two or three times daily for IR.

Procedural Structure for Discontinuation

The protocol for ending therapy involves a process where the dosage is reduced gradually under supervision. The daily dose is decreased by no more than 0.5 mg every 3 days to manage the transition, although a slower taper rate may be used for some individuals. This controlled reduction defines the final stage of the use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zolem (Omeprazole)

The research evidence for Zolem, the proprietary name for omeprazole, is rooted primarily in decades of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies was studied for use in conditions characterized by symptoms related to physiological strain or irritative states. The findings from this research describe group patterns and contribute to the broader evidence landscape, but they do not provide individual predictions or clinical guidance.


Evidence Overview: Studies for Erosive Esophagitis (EE)

Zolem was evaluated in research exploring the condition known as Erosive Esophagitis, where there is inflammation and damage to the lining of the food pipe.

  • What researchers studied: Researchers utilized multiple short-term RCTs with follow-up durations typically ranging from 4 to 8 weeks. The primary outcome measured in these studies was the observed resolution of mucosal breaks (confirmed endoscopically). Studies included adult patients and certain trials also included pediatric patients.
  • What the studies reported: Studies reported measured healing rates versus those observed with placebo treatments and older acid-reducing medications. The research highlights changes measured in the endoscopic appearance of the esophageal lining over the defined study period for many enrolled participants.
  • What remains uncertain: While short-term outcomes are reported, long-term follow-up regarding the durability of healing without continued administration is not fully established. Additionally, there are limited data for certain subgroups of patients with the most advanced forms of EE.

Evidence Overview: Studies for Symptomatic Gastroesophageal Reflux Disease (GERD)

Research also examined patient-reported experiences related to Symptomatic GERD, a condition characterized by fluctuating or episodic manifestations such as heartburn.

  • What researchers studied: Evidence comes mainly from short-term RCTs that usually followed patients for 2 to 4 weeks. Primary outcomes were patient-reported outcomes describing perceived discomfort, focusing on the frequency and intensity of symptoms like heartburn and acid regurgitation. Studies included adult populations with and without endoscopic signs of esophagitis.
  • What the studies reported: Trials reported how symptoms evolved in the observed populations, describing patterns such as a reduction in the frequency of reported reflux symptoms during the study periods. Some research also monitored physiological strain by reporting on changes in intragastric pH—a measured biomarker of acid suppression.

Evidence Overview: Studies for Maintenance Therapy and Long-Term Use

Research has been conducted to explore the role of longer-term use, particularly after acute healing has occurred. Intermediate to long-term RCTs (lasting up to one year) were conducted in populations who had already achieved initial healing. The main outcomes described were the observed rates of both endoscopic and symptomatic relapse (the symptoms or damage returning).

Key Studies & References

  1. Systematic review: proton pump inhibitors for the treatment of gastroesophageal reflux in infants
  2. Medical management of gastro-esophageal reflux in healthy infants (Canadian Paediatric Society Guideline)

Frequently Asked Questions (FAQ)

Common questions about Zolem (FAQ)


Q: Is Zolem prescribed for children or teenagers?

A: According to official product information, certain forms of this medication, such as the one used for acid suppression (Omeprazole), are included in pediatric treatment guidelines for specific diagnosed conditions.

However, other forms (Alprazolam, Zolpidem) generally state that safety or effectiveness in children and adolescents under 18 years of age have not been established in this population.


Q: Why do some people report feeling anxious after taking Zolem?

A: The official drug label lists paradoxical reactions, which are unexpected adverse events. These reactions have been reported to include symptoms such as agitation and anxiety in some patients.

This information is collected from clinical trials and is included in regulatory documents for review.


Q: How long does the effect of a single dose of Zolem last?

A: The clinical duration of effect is determined by the drug's purpose and formula.

For immediate-release forms of the substance, the elimination half-life (the time it takes for half the drug to be eliminated from the body) is generally reported to be approximately 11 hours. For the acid-blocking version, the effect on acid secretion can last for up to 72 hours, even though the substance itself clears the bloodstream more quickly.


Q: Are the generic versions of Zolem the same as the brand name?

A: Regulatory principles dictate that generic versions of a drug are required to meet the same quality and purity standards as the brand-name product.

Before approval by the FDA or equivalent body, generic versions must demonstrate bioequivalence, meaning they contain the same active ingredient and are intended to work in the body in a way that is therapeutically equivalent.


Q: Can I use Zolem if I am allergic to similar types of medication?

A: Official documentation states that this medication is strictly prohibited if a patient has a known hypersensitivity or allergic reaction to the drug itself or to other chemically or pharmacologically related drugs in its class.

The official guidance is that patients must disclose all known drug allergies to a healthcare professional before starting treatment.


Q: Is Zolem described as a drug that is only meant for short-term use?

A: The official indication and usage instructions vary by the drug form.

For some products, short-term use is specified, with clinical trials establishing defined periods of treatment duration. For forms used to treat anxiety, clinical studies have investigated effectiveness for use over periods up to several months.


Q: Does Zolem require any special monitoring while you are taking it?

A: The official product information indicates that regulatory documents recommend regular monitoring of patient progress, especially during long-term use.

Monitoring may include checks on symptoms, blood work, or assessments of organ function, such as liver or kidney health.


Q: Does Zolem have to be taken at a specific time of day?

A: Yes, depending on the drug's purpose, a specific timing is often required.

Forms used for sleep are typically required to be taken immediately before going to bed, provided the patient ensures they have a full 7 to 8 hours available for sleep. Forms used for acid suppression are often recommended to be taken before eating in the morning.


Q: What is the main thing Zolem is used for?

A: According to official drug labels, the active ingredient in Zolem is indicated for the treatment of various conditions, depending on the specific drug form.

These uses include the management of anxiety and panic disorder, short-term treatment of insomnia, or treatment of conditions like Gastroesophageal Reflux Disease (GERD) and ulcers.


Q: Why do people say Zolem is a 'Schedule X' drug?

A: This description refers to the drug's classification under the Controlled Substances Act, such as Schedule IV.

Drugs under this schedule are classified by regulatory bodies like the DEA due to their potential for abuse or dependence, as evaluated against their accepted medical uses.


Q: How long does it usually take to notice the effect of Zolem?

A: The speed of the effect depends on the specific formulation.

For immediate-release tablets, peak concentrations in the bloodstream are often measured within 30 minutes to two hours. For drugs that manage conditions like frequent heartburn, the full therapeutic effect may take several days to become noticeable.


Q: Does Zolem stay in your system for a long time?

A: The time a drug remains in the system is related to its half-life, which describes the time needed for elimination.

Based on official regulatory data, the mean plasma elimination half-life for the active substance ranges from approximately 2.6 hours up to 11.2 hours in most healthy adults.


Q: Is Zolem the same kind of drug as a benzodiazepine?

A: The drug name Zolem is used for different active substances with different classifications.

One form (Alprazolam) is classified as a benzodiazepine. Another form (Zolpidem) is classified as a non-benzodiazepine hypnotic, and a third form (Omeprazole) is a Proton Pump Inhibitor (a type of stomach acid blocker).


Q: Can you take Zolem if you already have kidney problems?

A: Official regulatory information notes that changes in kidney function can affect how the body processes the drug, which may result in altered clearance or effects in the body.

Some forms of the drug have also been associated with risks like acute kidney injury. Specific recommendations on duration and dosing for patients with kidney issues are determined by a healthcare provider.


Q: Is there a maximum time that Zolem is recommended for use?

A: Yes, regulatory documents specify recommended maximum treatment durations for various indications.

This may be a limited course of several weeks for certain uses or a specific course length for over-the-counter forms. The appropriate duration of use is determined by the specific condition being treated and a healthcare professional.


Q: What happens if someone takes too much Zolem by accident?

A: The overdosage section of the official drug label warns that taking too much can cause severe symptoms.

These may include extreme drowsiness, confusion, loss of coordination, respiratory depression, coma, and even death. If overdose is suspected, emergency medical assistance should be sought immediately.


Q: What does the FDA say about Zolem’s main use?

A: The FDA determines the approved indications based on research evidence provided by the manufacturer.

The official uses listed on the drug label—which include anxiety/panic, insomnia, and the treatment of GERD/ulcers—are the indications formally approved by the FDA.


Q: Does Zolem have any known effects on appetite or weight?

A: The adverse reactions sections in the official drug labels indicate that changes in appetite have been reported, including both increased and decreased appetite.

Correspondingly, changes in weight (both gain and loss) have also been reported as adverse events during clinical trials.


Q: What are the signs that Zolem might not be working as expected?

A: Official labeling provides guidance on monitoring therapeutic response.

Official instructions indicate that a healthcare provider should be contacted if the original symptoms do not start to get better or if they appear to be getting worse while using the medication.


Q: How often do people using Zolem report experiencing insomnia?

A: While one form of the drug is used to treat sleep issues, the adverse events tables for other forms of the drug list 'problems sleeping' (insomnia) as a potential side effect reported by some patients in clinical trials.

Specific frequency statistics for all reported side effects are available within the official regulatory documents.


Q: Is Zolem known to affect blood pressure?

A: Official adverse reaction reports from clinical trials indicate that low blood pressure, known medically as hypotension, has been reported as a side effect of the medication.

Official guidance recommends disclosing any history of blood pressure issues to a healthcare provider.


Q: Are there official statistics on the rate of reported side effects for Zolem?

A: Yes, the official drug labels contain specific data on reported side effects.

These labels include tables of adverse events from clinical trials, which list the percentages of patients who reported specific side effects compared to a placebo group.


Q: Are there known interactions between Zolem and over-the-counter pain relievers?

A: Regulatory documents emphasize the importance of caution when combining this medication with any other substances.

Official guidance recommends disclosing all prescription and over-the-counter medicines, vitamins, and supplements to a healthcare provider due to the potential for drug interactions.


Q: What does the official drug label say about missing a dose of Zolem?

A: The standard guidance in the official drug label provides the general instruction that a missed dose may be taken as soon as it is remembered.

However, if it is almost time for the next scheduled dose, the regulatory instruction is to skip the missed dose and resume the normal schedule without taking a double dose.

How should Zolem be stored and disposed of?

How to Store and Dispose of Zolem?

Zolem (Omeprazole) must be stored and disposed of according to labeled regulatory requirements to protect the product's stability and prevent misuse.


Storage Conditions

Item Requirement
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Protect from moisture and light.
Container Store in the original container and keep the cap tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Zolem must be disposed of in accordance with local requirements. The preferred method is using a drug take-back program. If this is unavailable, the medicine may be mixed with an unappealing substance (such as dirt) and sealed in a container for disposal in household trash. It is not recommended for disposal by flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolem found in:

A-Z Index: